PPARγ and RXR Ligands Disrupt the Inflammatory Cross-talk in the Hypoxic Breast Cancer Stem Cells Niche

Journal of Cellular Physiology

Volumn 229, Issue 11, 2014, Pages 1595-1606

  Papi, Alessio ^a   De Carolis, Sabrina ^b   Bertoni, Sara ^b   Storci, Gianluca ^b   Sceberras, Virginia ^a   Santini, Donatella ^a   Ceccarelli, Claudio ^a   Taffurelli, Mario ^a   Orlandi, Marina ^a   Bonafé, Massimiliano ^a,c,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CNR   (Italy)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 OH 11 O HYDROXYPHENANTHRENE; APOLIPOPROTEIN E; CARBONATE DEHYDRATASE IX; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JAGGED1; NOTCH3 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENANTHRENE DERIVATIVE; PIOGLITAZONE; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

APOLIPOPROTEIN E GENE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER STEM CELL; CANCER SURGERY; CANCER TISSUE; CARBONATE DEHYDRATASE IX GENE; CELL DISRUPTION; CELL HYPOXIA; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; EXOSOME; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA INDUCIBLE FACTOR 1ALPHA GENE; INTERLEUKIN 6 GENE; JAGGED1 GENE; MAMMARY GLAND; MASTECTOMY; MCF 7 CELL LINE; MOLECULAR INTERACTION; NOTCH3 RECEPTOR GENE; PHENOTYPE; PRIORITY JOURNAL; REGULATOR GENE; SEGMENTAL MASTECTOMY; STEM CELL NICHE;

ANTIGENS, NEOPLASM; APOLIPOPROTEINS E; BREAST NEOPLASMS; CARBONIC ANHYDRASES; CELL HYPOXIA; CELL SURVIVAL; EXOSOMES; FEMALE; FIBROBLASTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION; LIGANDS; MATRIX METALLOPROTEINASE 9; MCF-7 CELLS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; NF-KAPPA B; PHENANTHRENES; PPAR GAMMA; RECEPTOR CROSS-TALK; RETINOID X RECEPTORS; SPHEROIDS, CELLULAR; STEM CELL NICHE; STROMAL CELLS; THIAZOLIDINEDIONES; TUMOR MARKERS, BIOLOGICAL;

EID: 84904876378     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24601     Document Type: Article

References (56)

1. Acharya PS, Majumdar S, Jacob M, Hayden J, Mrass P, Weninger W, Assoian RK, Puré E. 2008. Fibroblast migration is mediated by CD44-dependent TGF beta activation. J Cell Sci 121:1393-1402.
2. Altucci L, Rossin A, Hirsch O, Nebbioso A, Vitoux D, Wilhelm E, Guidez F, De Simone M, Schiavone EM, Grimwade D, Zelent A, de Thé H, Gronemeyer H. 2005. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res 65:8754-8765.
3. Bonafè M, Storci G, Franceschi C. 2012. Inflamm-aging of the stem cell niche: Breast cancer as a paradigmatic example: Breakdown of the multi-shell cytokine network fuels cancer in aged people. Bioessays 34:40-49.
4. Bonofiglio D, Cione E, Qi H, Pingitore A, Perri M, Catalano S, Vizza D, Panno ML, Genchi G, Fuqua SA, Andò S. 2009. Combined low doses of PPARγ and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol 175:1270-1280.
5. Chen J, Chen LJ, Yang RB, Xia YL, Zhou HC, Wu W, Lu Y, Hu LW, Zhao Y. 2013. Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma. Med Oncol 30:583.
6. Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. 2013. Matrix metalloproteinases: Inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediat Inflamm 2013: 928315.
7. Chou TC. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharm Rev 58:621-681.
8. Conde-Vancells J, Rodriguez-Suarez E, Embade N, Gil D, Matthiesen R, Valle M, Elortza F, Lu SC, Mato JM, Falcon-Perez JM. 2008. Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res 7:5157-5166.
9. Coppé JP, Desprez PY, Krtolica A, Campisi J. 2010. The senescence-associated secretory phenotype: the dark side of tumour suppression. Annu Rev Pathol 5:99-118.
10. Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L. 2011. Intracellular and extracellular microRNAs in breast cancer. Clin Chem 57:18-32.
11. Dorai T, Sawczuk I, Pastorek J, Wiernik PH, Dutcher JP. 2006. Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: Proposal of a unified hypothesis. Cancer Invest 8:754-779.
12. Flannery CR. 2006. MMPs and ADAMTs: Functional studies. Front Biosci 11:544-569.
13. Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, Wicha MS, Birnbaum D, Charafe-Jauffret E. 2009. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 8:3297-3302.
14. Görlach A, Bonello S. 2008. The cross-talk between NF-κB and HIF-1: Further evidence for a significant liaison. Biochem J 412:e17-e19.
15. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zürrer-Härdi U, Bell G, et al. 2012. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148:1015-1028.
16. Hamma-Kourbali Y, Di Benedetto M, Ledoux D, Oudar O, Leroux Y, Lecouvey M, Kraemer M. 2003. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun 24:816-823.
17. Harrison H, Rogerson L, Gregson HJ, Brennan KR, Clarke RB, Landberg G. 2013. Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ERα status. Cancer Res 15:1420-1433.
18. Hendrix A, Hume AN. 2011. Exosome signaling in mammary gland development and cancer. Int J Dev Biol 55:879-887.
19. Kooijmans SA, Vader P, Van Dommelen SM, Van Solinge WW, Schiffelers RM. 2012. Exosome mimetics: A novel class of drug delivery systems. Int J Nanomedicine 7:1525-1541.
20. Korkaya H, Liu S, Wicha MS. 2011. Breast cancer stem cells, cytokine networks, and the tumour microenvironment. J Clin Invest 3:3804-3809.
21. Kotta-Loizou I, Giaginis C, Theocharis S. 2012. The role of peroxisome proliferator-activated receptor-γ in breast cancer. Anticancer Agents Med Chem 12:1025-1044.
22. Lee EK, Lee MJ, Abdelmohsen K, Kim W, Kim MM, Srikantan S, Martindale JL, Hutchison ER, Kim HH, Marasa BS, Selimyan R, Egan JM, Smith SR, Fried SK, Gorospe M. 2011. MiR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol 31:626-638.
23. Liu S, Wicha MS. 2010. Targeting breast cancer stem cells. J Clin Oncol 28:4006-4012.
24. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, et al. 2011. Targeting tumour hypoxia: suppression of breast tumour growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 71:3364-3376.
25. Mandard S, Patsouris D. 2013. Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. PPAR Res 2013:613864.
26. Nassour M, Idoux-Gillet Y, Selmi A, Côme C, Faraldo ML, Deugnier MA, Savagner P. 2012. Slug controls stem/progenitor cell growth dynamics during mammary gland morphogenesis. PLoS One 7:e53498.
27. Papi A, Tatenhorst L, Terwel D, Hermes M, Kummer MP, Orlandi M, Heneka MT. 2009. PPARγ and RXR ligands act sinergistically as potent antineoplastic agents in vitro and in vivo glioma models. J Neurochem 109:1779-1790.
28. Papi A, Rocchi P, Ferreri AM, Orlandi M. 2010. RXRγ and PPARγ Ligands in Combination to Inhibit Proliferation and Invasiveness in Colon Cancer Cells. Cancer Lett 297:65-72.
29. Papi A, Guarnieri T, Storci G, Santini D, Ceccarelli C, Taffurelli M, De Carolis S, Avenia N, Sanguinetti A, Sidoni A, et al. 2012. Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ 19:1208-1219.
30. Papi A, Storci G, Guarnieri T, De Carolis S, Bertoni S, Avenia N, Sanguinetti A, Sidoni A, Santini D, Ceccarelli C, et al. 2013. Peroxisome proliferator activated receptor-α/hypoxia inducible factor-1α interplay sustains carbonic anhydrase IX and apolipoprotein E expression in breast cancer stem cells. Plos One 8:e54968.
31. Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, Coscia C, Iessi E, Logozzi M, Molinari A, Colone M, et al. 2009. Microenvironmental pH is a key factor for exosome traffic in tumour cells. J Biol Chem 284:34211-34222.
32. Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, et al. 2012. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 18:883-891.
33. Peters JM, Shah YM, Gonzalez FJ. 2012. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 12:181-195.
34. Piperi C, Papavassiliou AG. 2012. Molecular mechanisms regulating matrix metalloproteinases. Curr Top Med Chem 12:1095-1112.
35. Podzielinski I, Saunders BA, Kimbler KD, Branscum AJ, Fung ET, Depriest PD, van Nagell JR, Ueland FR, Baron AT. 2013. Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancer. Cancer Invest 31:258-272.
36. Rankin EB, Giaccia AJ. 2011. The role of hypoxia-inducible factors in tumourigenesis. Cell Death Differ 15:678-685.
37. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M. 2008. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 453:807-811.
38. Ruan K, Fang X, Ouyang G. 2009. MicroRNAs: Novel regulators in the hallmarks of human cancer. Cancer Lett. 28:116-126.
39. Rucci N, Sanità P, Angelucci A. 2011. Roles of metalloproteases in metastatic niche. Curr Mol Med 11:609-622.
40. Rudnick JA, Arendt LM, Klebba I, Hinds JW, et al. 2011. Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells. PLoS One. 6:e24605.
41. Saito K, Kondo E, Matsushita M. 2011. MicroRNA 130 family regulates the hypoxia response signal through the P-body protein DDX6. Nucleic Acids Res 39:6086-6099.
42. Sansone P, Piazzi G, Paterini P, Strillacci A, Ceccarelli C, Minni F, Biasco G, Chieco P, Bonafè M. 2009. Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells. J Cell Mol Med 13:3876-3887.
43. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, et al. 2007. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117:3988-4002.
44. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al. 2007. Molecular definition of breast tumour heterogeneity. Cancer Cell 11:259-273.
45. Skelhorne-Gross G, Nicol CJ. 2012. The key to unlocking the chemotherapeutic potential of PPARγ ligands: Having the right combination. PPAR Res 946943.
46. Storci G, Sansone P, Mari S, D'Uva G, Tavolari S, Guarnieri T, Taffurelli M, Ceccarelli C, Santini D, Chieco P, Marcu KB, Bonafè M. 2010. TNFα up-regulates SLUG via the NF-κB/HIF1α axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol 225:682-691.
47. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S, Huang T, Chan MW, Marini FC, Rosol TJ, Bonafé M, Hall BM. 2008. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 68:9087-9909.
48. Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, Barnes S, Grizzle W, Miller D, Zhang HG. 2010. A novel nanoparticle drug delivery system: The anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 18:1606-1614.
49. Tanaka T, De Luca LM. 2009. Therapeutic potential of "rexinoids" in cancer prevention and treatment. Cancer Res 12:4945-4957.
50. Ward C, Langdon SP, Mullen P, Harris AL, Harrison DJ, Supuran CT, Kunkler IH. 2013. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev 39:171-179.
51. Westermarck J, Kähäri VM. 1999. Regulation of matrix metalloproteinase expression in tumour invasion. FASEB J 13:781-792.
52. Yamaji-Kegan K, Su Q, Angelini DJ, Myers AC, Cheadle C, Johns RA. 2010. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) increases lung inflammation and activates pulmonary microvascular endothelial cells via an IL-4-dependent mechanism. J Immunol 185:5539-5548.
53. Ye J, Gao Z, Yin J, He Q. 2007. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 293:1118-1128.
54. Youssef J, Badr M. 2011. Peroxisome proliferator-activated receptors and cancer: Challenges and opportunities. Br J Pharmacol 164:68-82.
55. Yue L, Rasouli N, Ranganathan G, Kern PA, Mazzone T. 2004. Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression. J Biol Chem 279:47626-47632.
56. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. 2008. NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 111:419-427.